ARS Pharmaceuticals Azioni (NASDAQ: SPRY)

ARS Pharmaceuticals (NASDAQ:SPRY) Azioni

ARS PHARMACEUTICALS INC

ARS Pharmaceuticals

ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.

ARS Pharmaceuticals Inc

WIIM

SDRL

Seadrill shares are trading lower following a Q1 EPS miss.

Goldman Sachs analyst Olivier Nicolai upgrades Anheuser-Busch InBev (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BUD#NYSE">BUD</a>) from Neutral to Buy and raises the price target from $70.1 to $88.

News

Upgrades

Price Target

Analyst Ratings

Goldman Sachs Upgrades Anheuser-Busch InBev to Buy, Raises Price Target to $88

<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4424402-1&amp;h=1455207525&amp;u=http%3A%2F%2Fwww.zynex.com%2F&amp;a=Zynex%2C+Inc">Zynex, Inc</a>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZYXI#NASDAQ">ZYXI</a>),&nbsp;an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced it has submitted a 510(k) application to the U.S. Food and Drug Administration ("FDA") for its NiCO&#x2122;, Noninvasive CO-Oximeter device.
This submission marks a historic milestone in the evolution of pulse oximetry and a major breakthrough for the Company in its mission to improve the quality of care and patient outcomes through its patient monitoring products. Pulse oximetry is one of the world's largest medical device markets and current devices on the market have long been under scrutiny for their inaccuracy and limitations. Zynex's laser technology enables oxygen levels to be measured accurately for patients with dark skin. In cases of carbon monoxide (CO) poisoning, not only are the measurements non-invasive and results instantaneous, but both oxygen and CO are measured accurately, potentially reducing the need for taking blood samples and having to wait for the lab results.
 &nbsp;

ZYXI

Zynex Submits 510(k) Application To FDA For NiCO, Noninvasive Co-Oximeter Device

LINC

Lincoln Educational Services shares are trading higher after the company reported better-than-expected Q1 financial results and raised its FY25 sales guidance above estimates.

As of May 12, 2025, two stocks in the information technology sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi">RSI is above 70</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>. 
Here's the latest list of major overbought players in this sector.
<h3 class="wp-block-heading">Astera Labs Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALAB#NASDAQ">ALAB</a>)</h3>
<ul class="wp-block-list">
<li>On May 6, Astera Labs posted better-than-expected quarterly results. &#8220;Astera Labs started the year strong, with Q1 revenue growing 13% sequentially and 144% year-over-year, and exceeding our first quarter guidance for gross margin and earnings per share,&#8221; said Jitendra Mohan, Astera Labs&#8217; Chief Executive Officer. The company's stock jumped around 20% over the past month and has a 52-week high of $147.39.</li>
<li>RSI Value: 70.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>ALAB Price Action: Shares of Astera Labs closed at $71.20 on Friday.</li>
<li>Edge Stock Ratings: 34.53 Momentum score with Value at 7.74. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/quote/ALAB"><img loading="lazy" decoding="async" width="486" height="157" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/12083959/image-120.png" alt="" class="wp-image-911845" style="width:375px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/12083959/image-120.png 486w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/12083959/image-120-300x97.png 300w" sizes="(max-width: 486px) 100vw, 486px" /></a></figure>
<h3 class="wp-block-heading">Microchip Technology Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCHP#NASDAQ">MCHP</a>)</h3>
<ul class="wp-block-list">
<li>On May 8, Microchip Technology reported better-than-expected fourth-quarter sales results and issued first-quarter EPS and revenue guidance above estimates. Steve Sanghi, Microchip&#8217;s CEO and President commented, Our March quarter revenue of $970.5 million exceeded the midpoint of our guidance, and we believe marks the bottom of this prolonged industry down cycle for Microchip.&#8221; The company's stock gained around 42% over the past month and <a href="https://www.benzinga.com/quote/MCHP">has a 52-week high</a> of $100.56.</li>
<li>RSI Value: 80.2</li>
<li>MCHP Price Action: Shares of Microchip Technology closed at $55.33 on Friday.</li>
</ul>
Curious about other BZ Edge Rankings? Click here to discover <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">how similar stocks measure up</a>. 
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/05/45342900/5-stock-picks-last-week-from-wall-streets-most-accurate-analysts-5">5 Stock Picks Last Week From Wall Street&#8217;s Most Accurate Analysts</a> </li>
</ul>
Photo via Shutterstock

Short Ideas

Pre-Market Outlook

Markets

ALAB

MCHP

Top 2 Tech Stocks That May Crash In Q2

Pan American Silver Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PAAS#NYSE">PAAS</a>) and MAG Silver Corp. (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MAG#AMEX">MAG</a>) disclosed a definitive deal for Pan American to acquire MAG Silver&#8217;s <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/b45339398/pan-american-silver-announces-agreement-to-acquire-mag-silver-corp" rel="noreferrer noopener">shares through a plan of arrangement</a>.
As per the deal, MAG shareholders will receive approximately $2.1 billion ($20.54 per MAG share based on PAAS&#8217;s May 9, 2025 NYSE closing price) in a mix of $500 million cash and 0.755 PAAS shares per MAG share (subject to proration).
This represents ~21% and ~27% premiums to MAG&#8217;s May 9, 2025 NYSEAM closing price and 20-day VWAP, respectively.
Also Read: <a href="https://www.benzinga.com/government/regulations/25/04/44903750/gold-price-soars-to-record-highs-eyes-best-2-month-rally-since-2011-on-blockbuster-etf-buying">Gold Price Soars To Record Highs, Eyes Best 2-Month Rally Since 2011 On Blockbuster ETF Buying</a>
Post-transaction, MAG shareholders will own ~14% of the enlarged, diversified Pan American, gaining exposure to a larger silver and gold producer.
The acquisition significantly enhances Pan American&#8217;s value by adding a 44% stake in Juanicipio, a premier, low-cost, high-grade silver mine in Mexico with substantial exploration potential, operated by Fresnillo.
This is expected to add forecasted production of 6.5-7.3 Moz of silver to Pan American Silver in 2025 and 58 Moz proven and probable reserves, 19 Moz measured and indicated resources, and 35 Moz inferred resources.
Notably, Juanicipio&#8217;s high-margin ounces, with projected 2025 cash costs of ($1.00)-$1.00/oz and all-in sustaining costs of $6.00-$8.00/oz, are a logical fit within Pan American&#8217;s Americas-focused silver portfolio.
The MAG acquisition should significantly boost Pan American&#8217;s 2025 free cash flow (+$98 million pro forma) and offer significant exploration upside (Juanicipio, Deer Trail, Larder), strategically deploying $500 million of PAAS&#8217;s cash for increased silver exposure and growth.
Michael Steinmann, President and CEO of Pan American, said, &#8220;Juanicipio is a large-scale, high-grade, low-cost silver mine that will meaningfully increase Pan American&#8217;s exposure to high-margin silver ounces. Furthermore, we see future growth opportunities through the significant exploration potential at Juanicipio as well as MAG&#8217;s Deer Trail and Larder properties. This strategic acquisition further solidifies Pan American as a leading Americas-focused silver producer.&#8221;
As of March 31, PAAS&#8217; cash and short-term <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/b45270191/pan-american-silver-reports-unaudited-first-quarter-2025-results" rel="noreferrer noopener">investments stood at $923.0 million</a>.
Price Action: PAAS shares are down 7.24% to $25.24, while MAG shares are up 13% to $19.12 premarket at the last check on Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com//node/45337711">Pony AI, Lyft And Sunrun Are Among Top 9 Mid-Cap Gainers Last Week (May 5-May 9): Are The Others In Your Portfolio?</a></li>
</ul>
Image via Shutterstock

Equities

Large Cap

Commodities

Movers

PAAS

Pan American Acquires MAG For $2.1 Billion

Lixte Biotech Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIXT#NASDAQ">LIXT</a>) reported quarterly losses of $(0.29) per share. This is a 32.56 percent increase over losses of $(0.43) per share from the same period last year.

Earnings

LIXT

Lixte Biotech Hldgs Q1 EPS $(0.29) Up From $(0.43) YoY

<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="900" height="600" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/12074722/MGM.jpeg" alt="" class="wp-image-12784" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/12074722/MGM.jpeg 900w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/12074722/MGM-300x200.jpeg 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/12074722/MGM-768x512.jpeg 768w" sizes="(max-width: 900px) 100vw, 900px" /></figure>
Once a favorite of investment banks for its strong post-pandemic performance, MGM China's business started to contract in the first quarter of 2025
<h4 class="wp-block-heading">Key Takeaways:</h4>
<ul class="wp-block-list">
<li>MGM China's revenue fell 3% in the first quarter, as Macao's post-pandemic rebound lost momentum</li>
<li>Revenue from the casino operator's VIP rooms plummeted by 50% during the quarter, far worse than a 10% decline for rival Sands China</li>
</ul>
After smiling on Macao for the last two years after China ended its strict pandemic restrictions, Lady Luck has found better places to cast her gaze these days than Asia's leading gambling enclave.
The city's gaming revenue began to slow down notably this year as the rebound faded and China's slowing economy further dampened demand, hurting business for its casino operators.&nbsp;MGM China Holdings Ltd.&nbsp;(2282.HK), previously an investor favorite, has become the latest to get dragged into the slowdown, reporting year-on-year revenue and profit declines its latest&nbsp;<a href="https://www1.hkexnews.hk/listedco/listconews/sehk/2025/0501/2025050100033.pdf">first-quarter results</a>.
The company's revenue slipped 3.2% to nearly HK$8 billion ($1.02 billion) in the three months to March, while its adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) sagged 5.5% to HK$2.37 billion, according to the report released earlier this month. The company blamed the revenue drop on a decrease in bets on main floor table games.
MGM China operates two casinos in Macao: the MGM Macao on the Macao Peninsula, where main floor table games bets decreased by 7.4% year-on-year during the quarter to HK$13.37 billion; and the MGM Cotai on the Cotai Strip, where main floor table games bets fell by nearly 4% to HK$14.85 billion.
<h4 class="wp-block-heading">VIP business plunge</h4>
While gaming was off on its main casino floors, the situation was even worse for its VIP business catering to high rollers. At MGM Macao, VIP turnover plunged by nearly half from HK$12.15 billion in the first quarter of 2024 to HK$6.24 billion in the first three months of this year. MGM Cotai's VIP turnover also halved from HK$53 billion to HK$26.27 billion over the period, suggesting that high-rollers weren't being as free-spending as they were during headier times when China's economy was booming.
While MGM China did not specify why its VIP business fell so sharply, rival&nbsp;Sands China&nbsp;(1928.HK) reported a much milder 10% year-on-year decline in its VIP revenue during the quarter. That seems to show that MGM China's VIP business plunge owned not only to lower traffic from China's high-rolling crowd, but also from competitors stealing its business.
Beyond its core gaming business, MGM China's hotel operations also sagged. Despite maintaining average occupancy rates of over 93% during the quarter, on par with a year earlier, the company's revenue per available room (revpar), which also factors in room prices, fell sharply. MGM Cotai's revpar dropped by 21% from HK$2,631 in the first quarter of 2024 to HK$2,066 in the latest period, while MGM Macao's revpar tumbled by an even higher 23% from HK$3,061 to HK$2,346 over that time.
<h4 class="wp-block-heading">Falling citywide revenue</h4>
While its VIP business is clearly facing company-specific issues, MGM China's bigger challenge – being faced by all in the market – is the broader Macao gaming market slowdown. All casino operators have also struggled to adjust following big changes in Macao's gaming regulations several years ago.
Those changes saw a ban on outsourcing VIP room operation, and limited junket operators to collect flat commissions from business they brought in without any profit-sharing. Meanwhile, China's own crackdown on marketing of cross-border gambling has further pressured the operators. Those factors, combined with the more recent economic slowdown, make it unlikely that Macao will ever return to its peak of 300 billion patacas ($37.4 billion) in annual gaming revenue.
The city's gross gaming revenue last month edged up 1.7% year-on-year to 18.86 billion patacas, but was down 4.1% month-on-month, marking a second consecutive sequential decline, according to the Macao Gaming Inspection and Coordination Bureau. That weakness is overshadowing the entire industry.
Macao's government estimated at the end of last year that gaming revenue would reach 240 billion patacas in 2025, up 11% year-on-year. To reach that figure, monthly gaming revenue would need to average 20 billion patacas. However, in the first four months of 2025, monthly gaming revenue has consistently fallen short of that amount, casting doubt on whether the annual target is attainable.
<h4 class="wp-block-heading">A lose-lose trade war</h4>
The U.S.-China trade war has also cast a shadow over Macao's gaming industry. While Macao doesn't conduct much direct trade with the U.S. and relies heavily on gaming for 80% of economic activity, the trade war is dragging down the whole global economy that supplies the gamblers who come to the city. Slowdowns in the Chinese and other global economies mean lower budgets for travel and consumption, which is likely to reduce the number of visitors to Macao, as well as their gaming budgets.
Macao's top government official Sam Hou Fai previously said escalation of the U.S.-China trade war would have limited direct impact on the city. But he also acknowledged that Macao could be affected indirectly by falling interest in the local tourism and gaming industries.
The economic impact of the U.S. tariff hikes has yet to clearly manifest itself, since the major increases occurred just last month. But many expect the effects to start showing up in the next six months to a year, with some countries like to report slipping into recession. Consumer sentiment is likely to weaken as that happens, further dampening demand for leisure travel.
When Macao's six major casino operators renewed their gaming licenses in 2023, MGM China was feted as the biggest winner, as the government boosted the company's licensed gaming tables by 36% to 750. That briefly made it an investor darling, as many bet the company would put those added tables to good use during the city's rebound. But with the industry now slowing, and pressure mounting on MGM China's VIP business, the casino operator, known for its lion logo, may rapidly be losing its roar.

Asia

Gaming

Opinion

Macao's Gaming Fatigue Takes The Roar Out Of MGM China

Canaccord Genuity analyst Maria Ripps maintains Nexxen International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEXN#NASDAQ">NEXN</a>) with a Buy and raises the price target from $12 to $14.

NEXN

Canaccord Genuity Maintains Buy on Nexxen International, Raises Price Target to $14

Goldman Sachs analyst Stephen Laszczyk downgrades Warner Music Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WMG#NASDAQ">WMG</a>) from Buy to Neutral and lowers the price target from $35 to $28.

Downgrades

Goldman Sachs Downgrades Warner Music Gr to Neutral, Lowers Price Target to $28

Northwest Bancshares, Inc. ("Northwest")&nbsp; (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWBI#NASDAQ">NWBI</a>), today announced a change in its board of directors as part of a leadership transition. As a result of his impending retirement from the board of directors in 2026, Timothy B. Fannin has stepped down as Board Chair, and has been succeeded by Vice Chair Timothy M. Hunter.

NWBI

Timothy Fannin Steps Down As Northwest Bancshares Chair, Succeeded By Timothy Hunter

Tharimmune (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THAR#NASDAQ">THAR</a>) reported quarterly losses of $(0.99) per share. This is a 61.18 percent increase over losses of $(2.55) per share from the same period last year.

THAR

Tharimmune Q1 EPS $(0.99) Up From $(2.55) YoY

Canaccord Genuity analyst William Plovanic maintains Zimmer Biomet Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZBH#NYSE">ZBH</a>) with a Hold and lowers the price target from $115 to $101.

Canaccord Genuity Maintains Hold on Zimmer Biomet Holdings, Lowers Price Target to $101

Redwire shares are trading higher after the company reported better-than-expected Q1 EPS results and issued FY25 sales guidance above estimates.

Stock Split

Neo-Concept International Approves 1-For-5 Reverse Stock Split To Consolidate All Issued And Unissued Class A And B Ordinary Shares By July 1, 2025, Reducing Authorized Share Count From 800M To 160M

BDRX

BDRX stock has given up its prior gain. Biodexa Pharmaceuticals shares were trading higher after the company received orphan drug designation in Europe for eRapa in treating familial adenomatous polyposis.

Rio Tinto Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RIO#NYSE">RIO</a>) shares are trading higher premarket on Monday after it finalized joint venture agreements with Sumitomo Metal Mining (SMM) to advance the Winu copper-gold project <a target="_blank" href="https://www.businesswire.com/news/home/20250511288741/en/Rio-Tinto-and-Sumitomo-Metal-Mining-sign-Definitive-Agreement-for-Winu-Project-joint-venture" rel="noreferrer noopener">in</a> Western Australia&#8217;s Great Sandy Desert.
According to the deal, Rio Tinto will remain responsible for the ongoing development and operation of the Winu project.
In return, Sumitomo Metal Mining will pay Rio Tinto up to $430.4 million for a 30% ownership stake in the project.
This includes an upfront payment of $195 million, with the potential for up to an additional $235.4 million in deferred payments contingent on achieving future project milestones.
Also Read: <a href="https://www.benzinga.com/news/management/25/05/45163353/rio-tinto-stops-activist-campaign-explores-critical-minerals-opportunities" target="_blank" rel="noreferrer noopener">Rio Tinto Stops Activist Campaign, Explores Critical Minerals Opportunities</a>
The transaction is anticipated to be finalized in 2025, pending regulatory approvals and standard closing conditions.
The Winu project, discovered by Rio Tinto in 2017, is described as an attractive, low-risk, long-life copper-gold deposit with significant potential for expansion beyond its initial development plans.
Rio Tinto is maintaining its focus on partnerships with the Nyangumarta and Martu Traditional Owners, including ongoing Project Agreement negotiations.
The pre-feasibility study for the Winu project, outlining an initial processing capacity of up to 10 million tonnes per annum (mtpa), is expected to be finalized in 2025.
Rio Tinto Copper Chief Executive Katie Jackson said, &#8220;Our relationship with SMM began in 2000 with our partnership at the Northparkes mine in New South Wales and we look forward to bringing our combined experience and expertise to deliver the Winu project.&#8221;
&#8220;This partnership is an excellent fit for Rio Tinto and will strengthen the project as we continue to prioritize the strong and enduring partnerships built to date with the land&#8217;s Traditional Owners, the Nyangumarta and the Martu.&#8221;
Last week, Rio Tinto disclosed that it entered into a Memorandum of Understanding (MoU) with&nbsp;AMG Metals &amp; Materials to explore the development of a large-scale,&nbsp;<a target="_blank" href="https://www.benzinga.com/news/contracts/25/04/44869614/why-is-rio-tinto-betting-on-india-a-green-aluminium-gamble-could-reshape-supply-chains" rel="noreferrer noopener">low-carbon aluminum project in India</a>.
Investors can gain exposure to the stock via&nbsp;VanEck Steel ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLX#NYSE">SLX</a>) and iShares Copper and Metals Mining ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICOP#NASDAQ">ICOP</a>).
Price Action: RIO shares are up 2.90% to $61.72 premarket at the last check on Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45163691/global-tensions-to-drive-a-two-year-copper-surplus-study-group-warns" target="_blank" rel="noreferrer noopener">Global Tensions To Drive Two-Year Copper Surplus, Study Group Warns</a></li>
</ul>
Image by Adwo via Shutterstock

ICOP

Rio Tinto, Sumitomo Partner On $430 Million Copper-Gold Project In Australia

Hut 8 shares are trading higher after the company announced that its subsidiary American Bitcoin will merge with Gryphon Digital.

<h3>Gainers</h3>
<table>
<thead>
<tr>
<th>Symbol</th>
<th>Name</th>
<th align="right">Price</th>
<th align="right">Change ($)</th>
<th align="right">Change (%)</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>)</td>
<td>SPDR Select Sector Fund - Consumer Discretionary</td>
<td align="right">213.3300</td>
<td align="right">10.92</td>
<td align="right">5.39</td>
<td>49.4K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>)</td>
<td>SPDR Select Sector Fund - Technology</td>
<td align="right">226.7900</td>
<td align="right">9.19</td>
<td align="right">4.22</td>
<td>155.8K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>)</td>
<td>SPDR Select Sector Fund - Energy Select Sector</td>
<td align="right">85.4399</td>
<td align="right">3.01</td>
<td align="right">3.65</td>
<td>179.9K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLI#NYSE">XLI</a>)</td>
<td>SPDR Select Sector Fund - Industrial</td>
<td align="right">140.2000</td>
<td align="right">4.09</td>
<td align="right">3.00</td>
<td>40.5K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NYSE">XLF</a>)</td>
<td>SPDR Select Sector Fund - Financial</td>
<td align="right">51.2100</td>
<td align="right">1.35</td>
<td align="right">2.70</td>
<td>890.8K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLB#NYSE">XLB</a>)</td>
<td>Materials Select Sector SPDR</td>
<td align="right">86.6200</td>
<td align="right">2.06</td>
<td align="right">2.43</td>
<td>20.6K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLC#NYSE">XLC</a>)</td>
<td>The Communication Services Select Sector SPDR Fund</td>
<td align="right">99.4600</td>
<td align="right">2.28</td>
<td align="right">2.34</td>
<td>4.0K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLRE#NYSE">XLRE</a>)</td>
<td>Real Estate Select Sector SPDR Fund (The)</td>
<td align="right">42.2500</td>
<td align="right">0.64</td>
<td align="right">1.53</td>
<td>4.2K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>)</td>
<td>SPDR Select Sector Fund - Utilities</td>
<td align="right">80.5201</td>
<td align="right">0.28</td>
<td align="right">0.34</td>
<td>67.7K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLP#NYSE">XLP</a>)</td>
<td>SPDR Select Sector Fund - Consumer Staples</td>
<td align="right">80.9500</td>
<td align="right">0.04</td>
<td align="right">0.04</td>
<td>256.0K</td>
</tr>
</tbody>
</table>
<h3>Losers</h3>
<table>
<thead>
<tr>
<th>Symbol</th>
<th>Name</th>
<th align="right">Price</th>
<th align="right">Change ($)</th>
<th align="right">Change (%)</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>)</td>
<td>SPDR Select Sector Fund - Health Care</td>
<td align="right">131.63</td>
<td align="right">-1.05</td>
<td align="right">-0.8</td>
<td>150.9K</td>
</tr>
</tbody>
</table>
<a href="https://pro.benzinga.com/?utm_source=insights">Pulled from Benzinga Pro data</a> this sector movers alert provides traders with a compiled way to read macro-level market trends. Investors garner a particular interest in sector movers to better determine sectors that are over- or under-performing to make better investing decisions on exchange-traded funds (ETFs) or individual tickers in those sectors. 
For more information on sector movers, <a href="https://www.benzinga.com/movers">click here</a>.

Sector ETFs

ETFs

XLRE

Select Sector SPDR-Consumer Discretionary

Leading And Lagging Sectors For May 12, 2025

Canaccord Genuity analyst Kyle Mikson maintains 10x Genomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXG#NASDAQ">TXG</a>) with a Buy and lowers the price target from $18 to $15.

Canaccord Genuity Maintains Buy on 10x Genomics, Lowers Price Target to $15

Press Releases

General

ARS Pharmaceuticals Launches neffyinSchools Program Providing Free Life-Saving Needle-Free Epinephrine For Emergency Use to Eligible K-12 Schools

ARS Pharmaceuticals to Participate in the Oppenheimer 35th Annual Healthcare Conference

ARS Pharmaceuticals to Showcase Innovation and Present Data on neffy® (epinephrine nasal spray) at 2025 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Scientific Meeting

Health Care

ARS Pharmaceuticals Announces OptumRx, Cigna Healthcare and Navitus Health Systems Add neffy® (Epinephrine Nasal Spray) to National Formularies, Further Expanding Coverage for Patients

ARS Pharmaceuticals Announces Conference Call and Webcast for its Fourth Quarter and Full Year 2024 Financial Results and Participation at Upcoming Conferences

ARS Pharmaceuticals Announces FDA Approval of neffy® 1 mg (epinephrine nasal spray) for Type I Allergic Reactions, Including Anaphylaxis, in Pediatric Patients Weighing 15 to < 30 Kilograms

ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

ARS Pharmaceuticals Announces Co-Promotion Agreement with Partner and Global Allergy Leader ALK-Abelló A/S to Expand Reach of neffy® (epinephrine nasal spray) to Additional U.S. Pediatricians

ARS Pharmaceuticals Announces Conference Call and Webcast for its First Quarter 2025 Financial Results

ARS Pharmaceuticals' neffy® (epinephrine nasal spray) 1 mg is Now Available in the United States for Type I Allergic Reactions, including Anaphylaxis, in Pediatric Patients Weighing 15 to < 30 Kilograms

Comments

ARS Pharmaceuticals

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO